SCHEMBL4920489

SCHEMBL4920489

CS(=O)(=O)Nc1cccc(Nc2nc(N3CCN(c4ccncc4)CC3)c3nc[nH]c3n2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 3/20 0.48
PIK3CA P42336 2/20 0.46
PIK3CG P48736 1/20 0.46
CHEK1 O14757 5/20 0.43
JAK2 O60674 3/20 0.42
PTK2 Q05397 7/20 0.42
JAK3 P52333 2/20 0.41
LCK P06239 1/20 0.41
FYN P06241 1/20 0.41
FES P07332 1/20 0.41
RET P07949 1/20 0.41
ROS1 P08922 1/20 0.41
CDK4 P11802 1/20 0.41
SRC P12931 1/20 0.41
JAK1 P23458 1/20 0.41
TYK2 P29597 1/20 0.41
EPHB1 P54762 1/20 0.41
CSNK2A1 P68400 1/20 0.41
DDR1 Q08345 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4914681 0.89 BRD4 (0.53) BRD4PIK3CAPIK3CGJAK2PTK2
SCHEMBL4917022 0.89 PIK3CA (0.46) BRD4PIK3CAPIK3CGCHEK1JAK2
SCHEMBL4919616 0.88 PIK3CA (0.57) BRD4PIK3CAPIK3CGCHEK1JAK2
SCHEMBL4917631 0.81 PTK2 (0.47) BRD4PIK3CAPIK3CGJAK2PTK2
SCHEMBL4917865 0.78 PTK2 (0.38) BRD4PIK3CAPIK3CGCHEK1JAK2
SCHEMBL4917337 0.77 PTK2 (0.40) BRD4PIK3CAPIK3CGCHEK1JAK2
SCHEMBL4649832 0.76 PTK2 (0.50) BRD4JAK2PTK2JAK3RET
SCHEMBL4916439 0.76 ADORA3 (0.42) BRD4PIK3CAPIK3CGJAK2PTK2
SCHEMBL4916388 0.76 ADORA3 (0.42) BRD4PIK3CAPIK3CGJAK2PTK2
SCHEMBL4916441 0.75 PTK2 (0.38) BRD4PIK3CAPIK3CGCHEK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors NOVARTIS AG (CH) 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261973-A1 Sulphonamidoaniline Derivatives Being Janus Kinase Inhibitors GRK4, JAK2, ALK BRD4 93/4885PIK3CA 635/4885PIK3CG 1751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.